by Michael King
The ongoing sequencing of the human genome was a positive for the genomics group in 2000 — enough to drive tens of IPOs. But the subsequent lack of immediate results in drug development soured the taste of many investors in 2001 and left fortunes waning at the infant companies.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.